Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8273 vs Erlotinib or Gefitinib in EGFR-Mutated NSCLC
NCT02588261Phase 3Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of naquotinib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Started Feb 2016; status: terminated.
02
Drugs
naquotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02588261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588261.